Blog
Valuable TargetsAdvanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
G-NDP803 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
G-NDP803 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
G-NDP803: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
CIGB-228 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
CIGB-228 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
CIGB-228: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
ALY-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
ALY-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
ALY-101: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
VI-0810 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
VI-0810 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
VI-0810: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
GCWB211 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
GCWB211 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
GCWB211: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
EDE-1205 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
EDE-1205 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
EDE-1205: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
GSK-5101956 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
GSK-5101956 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
GSK-5101956: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
LT-4008 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
LT-4008 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
LT-4008: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
[18F]THK-5105 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
[18F]THK-5105 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
[18F]THK-5105: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
SIS-302-AA Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
SIS-302-AA Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
SIS-302-AA: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Recombinant lipase(Groupe Mayoly Spindler) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
Recombinant lipase(Groupe Mayoly Spindler) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
Recombinant lipase(Groupe Mayoly Spindler): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
VEGFR-1/2 peptide vaccine(Keio University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
VEGFR-1/2 peptide vaccine(Keio University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
VEGFR-1/2 peptide vaccine(Keio University): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →